298 related articles for article (PubMed ID: 22893357)
21. Vitamin D status and parathyroid hormone concentrations influence the skeletal response to zoledronate and denosumab.
Mosali P; Bernard L; Wajed J; Mohamed Z; Ewang M; Moore A; Fogelman I; Hampson G
Calcif Tissue Int; 2014 May; 94(5):553-9. PubMed ID: 24509506
[TBL] [Abstract][Full Text] [Related]
22. Acute and long-term effects of zoledronate in adult patients with osteogenesis imperfecta. An observational Spanish study with five years of follow-up.
Pavón de Paz I; Rosado Sierra JA; Pérez Blanco C; Modroño Móstoles N; Guijarro de Armas G; Navea Aguilera C
Endocrinol Diabetes Nutr (Engl Ed); 2019 Feb; 66(2):108-116. PubMed ID: 30077631
[TBL] [Abstract][Full Text] [Related]
23. Clinical Research of the Application of Bone Turnover Markers in Monitoring the Short-Term Therapeutic Efficacy of Vitamin D in Postmenopausal Osteoporotic women in Harbin, China.
Zhang Y; Wang Y
J Nutr Health Aging; 2020; 24(5):485-493. PubMed ID: 32346686
[TBL] [Abstract][Full Text] [Related]
24. Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: a randomized controlled trial.
McClung M; Miller P; Recknor C; Mesenbrink P; Bucci-Rechtweg C; Benhamou CL
Obstet Gynecol; 2009 Nov; 114(5):999-1007. PubMed ID: 20168099
[TBL] [Abstract][Full Text] [Related]
25. Duration of antiresorptive effects of low-dose zoledronate in osteopenic postmenopausal women: a randomized, placebo-controlled trial.
Grey A; Bolland M; Mihov B; Wong S; Horne A; Gamble G; Reid IR
J Bone Miner Res; 2014 Jan; 29(1):166-72. PubMed ID: 23761303
[TBL] [Abstract][Full Text] [Related]
26. Dose-response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis.
Nakamura T; Matsumoto T; Sugimoto T; Shiraki M
Osteoporos Int; 2012 Mar; 23(3):1131-40. PubMed ID: 21927920
[TBL] [Abstract][Full Text] [Related]
27. Relationship between bone mineral density changes and risk of fractures among patients receiving calcium with or without vitamin D supplementation: a meta-regression.
Rabenda V; Bruyère O; Reginster JY
Osteoporos Int; 2011 Mar; 22(3):893-901. PubMed ID: 21060990
[TBL] [Abstract][Full Text] [Related]
28. Effects of milk powder intervention on bone mineral density and indicators related to bone metabolism in Chinese adolescents.
Lu JX; Pan H; Hu XQ; Huang ZW; Zhang Q
Osteoporos Int; 2019 Nov; 30(11):2231-2239. PubMed ID: 31375874
[TBL] [Abstract][Full Text] [Related]
29. Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial.
McClung MR; Lewiecki EM; Geller ML; Bolognese MA; Peacock M; Weinstein RL; Ding B; Rockabrand E; Wagman RB; Miller PD
Osteoporos Int; 2013 Jan; 24(1):227-35. PubMed ID: 22776860
[TBL] [Abstract][Full Text] [Related]
30. Fracture Prevention with Zoledronate in Older Women with Osteopenia.
Reid IR; Horne AM; Mihov B; Stewart A; Garratt E; Wong S; Wiessing KR; Bolland MJ; Bastin S; Gamble GD
N Engl J Med; 2018 Dec; 379(25):2407-2416. PubMed ID: 30575489
[TBL] [Abstract][Full Text] [Related]
31. THE CLINICAL CHARACTERISTICS AND EFFICACY OF BISPHOSPHONATES IN AUDLT PATIENTS WITH OSTEOGENESIS IMPERGECTA.
Xu XJ; Ma DD; Lv F; Wang JY; Liu Y; Xia WB; Jiang Y; Wang O; Xing XP; Yu W; Li M
Endocr Pract; 2016 Nov; 22(11):1267-1276. PubMed ID: 27482615
[TBL] [Abstract][Full Text] [Related]
32. The levels of bone turnover markers 25(OH)D and PTH and their relationship with bone mineral density in postmenopausal women in a suburban district in China.
Gao C; Qiao J; Li SS; Yu WJ; He JW; Fu WZ; Zhang ZL
Osteoporos Int; 2017 Jan; 28(1):211-218. PubMed ID: 27468899
[TBL] [Abstract][Full Text] [Related]
33. Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC.
Hines SL; Mincey B; Dentchev T; Sloan JA; Perez EA; Johnson DB; Schaefer PL; Alberts S; Liu H; Kahanic S; Mazurczak MA; Nikcevich DA; Loprinzi CL
Breast Cancer Res Treat; 2009 Oct; 117(3):603-9. PubMed ID: 19214743
[TBL] [Abstract][Full Text] [Related]
34. A phase 2 study of MK-5442, a calcium-sensing receptor antagonist, in postmenopausal women with osteoporosis after long-term use of oral bisphosphonates.
Cosman F; Gilchrist N; McClung M; Foldes J; de Villiers T; Santora A; Leung A; Samanta S; Heyden N; McGinnis JP; Rosenberg E; Denker AE
Osteoporos Int; 2016 Jan; 27(1):377-86. PubMed ID: 26556736
[TBL] [Abstract][Full Text] [Related]
35. Favorable effect of dietary vitamin C on bone mineral density in postmenopausal women (KNHANES IV, 2009): discrepancies regarding skeletal sites, age, and vitamin D status.
Kim YA; Kim KM; Lim S; Choi SH; Moon JH; Kim JH; Kim SW; Jang HC; Shin CS
Osteoporos Int; 2015 Sep; 26(9):2329-37. PubMed ID: 25906241
[TBL] [Abstract][Full Text] [Related]
36. The seasonal importance of serum 25-hydroxyvitamin D for bone mineral density in older women.
Michaëlsson K; Wolk A; Byberg L; Mitchell A; Mallmin H; Melhus H
J Intern Med; 2017 Feb; 281(2):167-178. PubMed ID: 27665750
[TBL] [Abstract][Full Text] [Related]
37. Threshold Effects of Vitamin D Status on Bone Health in Chinese Adolescents With Low Calcium Intake.
Wu F; Laslett LL; Zhang Q
J Clin Endocrinol Metab; 2015 Dec; 100(12):4481-9. PubMed ID: 26465394
[TBL] [Abstract][Full Text] [Related]
38. The first multicenter and randomized clinical trial of herbal Fufang for treatment of postmenopausal osteoporosis.
Zhu HM; Qin L; Garnero P; Genant HK; Zhang G; Dai K; Yao X; Gu G; Hao Y; Li Z; Zhao Y; Li W; Yang J; Zhao X; Shi D; Fuerst T; Lu Y; Li H; Zhang X; Li C; Zhao J; Wu Q; Zhao SJ
Osteoporos Int; 2012 Apr; 23(4):1317-27. PubMed ID: 21505910
[TBL] [Abstract][Full Text] [Related]
39. Relationship between increased endogenous parathormone levels and bone density in postmenopausal women treated with bisphosphonates.
Coin A; Veronese N; Bolzetta F; De Rui M; Manzato E; Sergi G
Panminerva Med; 2012 Dec; 54(4):277-82. PubMed ID: 23123579
[TBL] [Abstract][Full Text] [Related]
40. Additive effects of nutritional supplementation, together with bisphosphonates, on bone mineral density after hip fracture: a 12-month randomized controlled study.
Flodin L; Sääf M; Cederholm T; Al-Ani AN; Ackermann PW; Samnegård E; Dalen N; Hedström M
Clin Interv Aging; 2014; 9():1043-50. PubMed ID: 25045257
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]